Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1-Reference-Cited by-同舟云学术

Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1

Published:2019-08 Issue:33 Volume:294 Page:12534-12546
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Deuss Felix A.,Watson Gabrielle M.^ORCID,Goodall Katharine J.,Leece Isobel,Chatterjee Sayantani,Fu Zhihui,Thaysen-Andersen Morten,Andrews Daniel M.,Rossjohn Jamie,Berry Richard^ORCID

Funder

Department of Health | National Health and Medical Research Council (NHMRC)

Department of Education and Training | Australian Research Council (ARC)

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference53 articles.

1. The Ly49 natural killer cell receptors: a versatile tool for viral self-discrimination;Berry;Immunol. Cell Biol,2014

2. The expanding spectrum of ligands for leukocyte Ig-like receptors;Burshtyn;J. Immunol,2016

3. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations;Campbell;Immunology,2011

4. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance;Borrego;Immunol. Res,2006

5. Complexity and diversity of the NKR-P1:Clr (Klrb1:Clec2) recognition systems;Kirkham;Front. Immunol,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD155 as an emerging target in tumor immunotherapy;International Immunopharmacology;2024-04

2. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells;International Immunology;2024-01-30

3. MD Simulation Reveals Regulation of Mechanical Force and Extracellular Domain 2 on Binding of DNAM-1 to CD155;Molecules;2023-03-21

4. Nectin Family Ligands Trigger Immune Effector Functions in Health and Autoimmunity;Biology;2023-03-15

5. CD155 in tumor progression and targeted therapy;Cancer Letters;2022-10